image credit: Freepik

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

April 29, 2021


A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The team analyzed the impact of potential mutations in the spike receptor-binding domain (RBD) on antibody efficacy. The study is currently available on the bioRxiv* preprint server.

Read More on The Medical News